Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • Arna Pharma and Slate Run complete JV for new US company
  • M&A / Deals

Arna Pharma and Slate Run complete JV for new US company

Pharmaceutical Technology

Arna Pharma and Slate Run Pharmaceuticals have completed a JV to form a company focusing on branded products and 505(b)(2) medicines.

Read full story

pharminent May 15, 2026

Pharmaceutical Technology

Arna Pharma and Slate Run Pharmaceuticals have completed a JV to form a company focusing on branded products and 505(b)(2) medicines.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Lilly UK recruits ex-England cricketer as obesity champion
Next: FDA approves Enhertu for two HER2-positive early breast cancer indications

Related Stories

  • M&A / Deals

Immunai and Boehringer partner to identify T-cell targets

pharminent June 26, 2026
  • M&A / Deals

Ionis grants Recordati rights to zilganersen for Alexander disease

pharminent June 26, 2026
  • M&A / Deals

Merck buys life sciences firm Bio-Techne in $11.3bn deal

pharminent June 25, 2026

You May Have Missed

  • News

Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and Zepbound

pharminent June 26, 2026
  • News

Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms

pharminent June 26, 2026
  • Regulatory

Replimune gets early August decision date for twice-rejected melanoma drug

pharminent June 26, 2026
  • Pipeline

Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms

pharminent June 26, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.